Understanding Rare Presentations of Skull Metastasis from HCC

Hepatocellular carcinoma (HCC) is widely recognized as one of the most aggressive primary malignancies of the liver. While its typical metastatic pathways involve the lungs, regional lymph nodes, and the adrenal glands, unusual presentations can often baffle clinicians. One such rare phenomenon is skull metastasis from HCC occurring as the initial clinical manifestation. In many instances, patients present with a palpable scalp mass or focal neurological deficits long before any liver-related symptoms appear. This diagnostic sequence is counterintuitive because skeletal involvement usually signifies an advanced stage of the disease. Consequently, a high index of suspicion is required when evaluating scalp lesions, particularly in regions where chronic hepatitis B or C is endemic. Early detection of the primary liver tumor following the discovery of a cranial lesion is vital for establishing a comprehensive treatment plan. This article explores the diagnostic hurdles and therapeutic pathways for patients presenting with this unique oncological challenge.

Pathophysiology and Prevalence: Why the Skull?

The incidence of skeletal metastasis in patients with hepatocellular carcinoma ranges from 16% to 39%, but the skull is affected in only 0.4% to 1.6% of these cases. Traditionally, the vertebral column and ribs are the most frequent sites of bone involvement due to their proximity to the primary tumor and the venous drainage patterns. However, the mechanism of spread to the calvaria is thought to involve the Batson venous plexus. This valveless system of veins connects the deep pelvic and thoracic veins to the internal vertebral venous plexuses, allowing cancer cells to bypass the pulmonary circulation. Furthermore, the rich blood supply and cytokine environment within the bone marrow of the skull may provide a hospitable niche for circulating HCC cells. Although the presentation of a solitary skull lesion is an outlier in clinical practice, its discovery should prompt an immediate and thorough systemic investigation. Understanding these pathways helps clinicians recognize that even a seemingly isolated scalp swelling could be a sentinel sign of underlying visceral malignancy. Moreover, recent therapeutic advances have extended the survival of HCC patients, which paradoxically leads to an increased observation of rare distant metastases that were previously unseen in clinical settings.

Diagnostic Challenges: Differentiating Scalp Masses

The primary hurdle in managing skull metastasis from HCC is the high risk of misdiagnosis. Scalp masses are frequently encountered in general practice and are often initially treated as benign conditions, such as sebaceous cysts, lipomas, or even meningiomas. In the case of metastatic HCC, the lesion often appears as a rapidly enlarging, painless mass that may erode the bone and extend into the intracranial space. Because these tumors are often hypervascular, they can mimic the appearance of a primary bone tumor or a vascular malformation. If a biopsy or surgical excision is performed without a prior diagnostic workup, significant intraoperative hemorrhage can occur. Therefore, it is essential to perform a comprehensive physical examination and review the patient’s history for risk factors such as cirrhosis or chronic viral hepatitis. The absence of jaundice or abdominal pain does not rule out HCC, as many metastatic cases involve relatively preserved liver function. Clinicians must prioritize a multidisciplinary review to avoid the pitfalls of premature surgical intervention on an unidentified secondary lesion.

Imaging and Workup: Identifying the Primary Source

Modern imaging techniques are the cornerstone of identifying the extent of calvarial lesions and locating the primary site. Computed Tomography (CT) typically reveals an osteolytic, destructive mass with poorly defined margins, often involving both the inner and outer tables of the skull. Magnetic Resonance Imaging (MRI) provides superior detail regarding intracranial extension and the relationship of the tumor to the underlying dura mater and brain parenchyma. A hallmark feature of metastatic HCC on MRI is its hyperintensity on T2-weighted images and significant enhancement following contrast administration. Furthermore, flow voids may be visible, indicating the hypervascular nature of the tumor. Once a suspicious skull lesion is identified, a triple-phase contrast-enhanced CT of the abdomen or a dynamic MRI of the liver is mandatory. These scans often reveal the primary hepatic lesion, even in patients with normal alpha-fetoprotein (AFP) levels. PET-CT may also be utilized to rule out other sites of systemic dissemination, ensuring that the treatment approach is tailored to the total disease burden. This systematic imaging approach ensures that the surgical and oncological teams are fully prepared for the complexity of the case.

Therapeutic Interventions: The Role of En Bloc Resection

The management of a solitary skull metastasis requires an aggressive and multifaceted strategy. While systemic therapy is necessary for the underlying HCC, local control of the cranial lesion is often prioritized to alleviate neurological symptoms and prevent further bone destruction. Surgical intervention, specifically an en bloc resection with a wide margin of healthy bone, is the preferred approach for solitary lesions. This technique reduces the risk of local recurrence and provides immediate decompression of the brain if intracranial extension is present. Following resection, cranioplasty using titanium mesh or bone cement is often required to restore the structural integrity of the skull. In cases where the primary liver tumor is also resectable, a dual surgical approach can significantly improve the patient's quality of life. However, if the primary disease is advanced, palliative options such as focal radiotherapy or transarterial chemoembolization (TACE) may be considered. These modalities aim to control tumor growth and manage pain while the patient undergoes systemic treatments like sorafenib or newer immunotherapy combinations. The choice of therapy must be individualized, balancing the benefits of local control against the overall prognosis of the patient.

Prognostic Outlook and Multidisciplinary Care

The prognosis for patients with metastatic HCC has historically been poor, with median survival times often measured in months. However, the emergence of a solitary skull metastasis as the initial symptom provides a unique window for early intervention. If the primary liver tumor is small and the metastasis is truly isolated, aggressive multidisciplinary care can lead to surprisingly favorable outcomes. This approach involves seamless collaboration between neurosurgeons, hepatologists, oncologists, and radiologists. Post-surgical management often includes chemotherapy or targeted molecular therapies to address microscopic systemic disease. Regular follow-up with serial imaging of both the head and abdomen is essential to detect any recurrence early. Furthermore, supportive care and rehabilitation are vital for patients who have experienced neurological impairment. Despite the aggressive nature of hepatocellular carcinoma, the integration of surgical excellence and modern oncological protocols offers hope for extending survival and maintaining a high quality of life. This case highlights that while a skull mass may seem like a minor cosmetic concern, it can be the key to diagnosing and treating a life-threatening internal malignancy.

Frequently Asked Questions

What are the characteristic imaging features of skull metastasis from HCC?

Imaging of skull metastasis from HCC typically shows an osteolytic lesion that destroys the bone and often extends into the scalp or intracranial space. On CT scans, these lesions appear as hyperdense, vascular masses with significant bone erosion. MRI provides a clearer view of dural involvement, showing hyperintensity on T2-weighted sequences and strong enhancement. The presence of flow voids within the tumor often suggests its highly vascular nature, which is a common characteristic of HCC.

How common is a solitary skull lesion as the initial symptom of liver cancer?

A solitary skull lesion as the first manifestation of hepatocellular carcinoma is extremely rare, occurring in less than 2% of patients with bone metastases. In most cases, HCC is diagnosed based on abdominal symptoms or routine screening. However, in endemic areas or in patients with asymptomatic liver disease, the cranial lesion may be the first clinical sign. This emphasizes the importance of including metastatic malignancy in the differential diagnosis of any enlarging scalp mass.

What is the recommended surgical approach for isolated calvarial HCC metastasis?

The recommended approach for an isolated calvarial metastasis is aggressive en bloc resection with wide margins. This involves removing the tumor along with a segment of healthy bone to ensure complete excision. If the tumor has invaded the dura or extended intracranially, a multidisciplinary team including neurosurgeons must perform the surgery. This is followed by skull reconstruction and subsequent systemic therapy, such as targeted agents or immunotherapy, to manage the primary liver tumor and any occult dissemination.

Disclaimer: This content is for informational and educational purposes only. It is not intended to provide specific medical advice or to substitute for the professional judgment of a healthcare provider. Readers should consult with a qualified medical professional for diagnosis and treatment of any medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Chugh A et al. Solitary Skull Metastasis as Initial Presentation of Hepatocellular Carcinoma: A Rare Case Report and Management Review. Ann Afr Med. 2026 Jul 03. doi: 10.4103/aam.aam_288_26. PMID: 42397699.

Long X et al. Scalp & Skull Metastasis in Hepatocellular Carcinoma. Oncol Target Ther. 2022;15:1581-1591. doi: 10.2147/OTT.S368143.

Parraga S et al. Metastatic hepatocellular carcinoma presenting as a lytic calvarial mass. Clin Case Rep. 2024;12(9):e9421. doi: 10.1002/ccr3.9421.

Zakaria R et al. Skull base metastasis as initial presentation of hepatocellular carcinoma. Surg Neurol Int. 2023;14:298. doi: 10.25259/SNI_614_2023.